RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

It operates via the same general mechanism, but so far as I know, has different composition of matter, and by the time it could be commercialized for some indication, the relevant use patents will have expired. Cortex has copyrighted 'AMPAkine' I believe, but I don't think they see going after copyright infringement for the use of that word (which I've seen used by others a couple of times) as being worthwhile.

So they are not entitled to anything other than some implicit validation--that the more companies that have an interest in AMPA upregulation of the allosteric variety, that perhaps their portfolio of molecules has some value. But in this day and age, you generally have to prove it in the clinic, not via 'geneaology.' There have been examples, most recently large molecules, antibodies, where a partner could be attracted simply by virtue of the mechanism and some animal validation. Not so with small molecules.

NeuroInvestment